![logo](/logos/0013.HK.webp)
HUTCHMED (China) Limited
HKEX:0013.HK
27.85 (HKD) • At close September 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | HUTCHMED (China) Limited |
Symbool | 0013.HK |
Munteenheid | HKD |
Prijs | 27.9 |
Beurswaarde | 24,314,004,630 |
Dividendpercentage | 0% |
52-weken bereik | 19 - 35.9 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Wei-Guo Su B.Sc., Ph.D. |
Website | https://www.hutch-med.com |
An error occurred while fetching data.
Over HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)